| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 23, 2009
From the Cardiovascular Magnetic Resonance Unit (P.K., M.A.T., J.P., D.W., J.T., M.A.W., L.J.A., D.J.P.) and Medical Statistics Department (M.R.), Imperial College and Royal Brompton Hospital, and Department of Hematology (J.B.P.) and Hatter Cardiovascular Institute (J.M.W.), University College London, London, UK. * To whom correspondence should be addressed. E-mail: d.pennell{at}ic.ac.uk.
Background—The goal of this study was to determine the predictive value of cardiac T2* magnetic resonance for heart failure and arrhythmia in thalassemia major. Methods and Results—We analyzed cardiac and liver T2* magnetic resonance and serum ferritin in 652 thalassemia major patients from 21 UK centers with 1442 magnetic resonance scans. The relative risk for heart failure with cardiac T2* values <10 ms (compared with >10 ms) was 160 (95% confidence interval, 39 to 653). Heart failure occurred in 47% of patients within 1 year of a cardiac T2* <6 ms with a relative risk of 270 (95% confidence interval, 64 to 1129). The area under the receiver-operating characteristic curve for predicting heart failure was significantly greater for cardiac T2* (0.948) than for liver T2* (0.589; P<0.001) or serum ferritin (0.629; P<0.001). Cardiac T2* was <10 ms in 98% of scans in patients who developed heart failure. The relative risk for arrhythmia with cardiac T2* values <20 ms (compared with >20 ms) was 4.6 (95% confidence interval, 2.66 to 7.95). Arrhythmia occurred in 14% of patients within 1 year of a cardiac T2* of <6 ms. The area under the receiver-operating characteristic curve for predicting arrhythmia was significantly greater for cardiac T2* (0.747) than for liver T2* (0.514; P<0.001) or serum ferritin (0.518; P<0.001). The cardiac T2* was <20 ms in 83% of scans in patients who developed arrhythmia. Conclusions—Cardiac T2* magnetic resonance identifies patients at high risk of heart failure and arrhythmia from myocardial siderosis in thalassemia major and is superior to serum ferritin and liver iron. Using cardiac T2* for the early identification and treatment of patients at risk is a logical means of reducing the high burden of cardiac mortality in myocardial siderosis.
Accepted on September 4, 2009
Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
P. Kirk MB, MRCP,
Related Articles:
Circulation 2009 120: 1935-1936.
Circulation 2009 120: 1937-1939.
This article has been cited by other articles:
![]() |
J. C. Wood History and Current Impact of Cardiac Magnetic Resonance Imaging on the Management of Iron Overload Circulation, November 17, 2009; 120(20): 1937 - 1939. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |